TGFB1 and Cachexia: We treated TGFBR inhibitor, SB431542 [[51], [52], [53]], in cachexia model and found that TGF-β blockade did not affect the population of p16high APCs without the effects on food intake, adipose weight, and body weight (Supplementary Fig. 9C–9F).